Product Announcement.
Click for Full Prescribing Information, including Indication, BOXED WARNING, and Important Safety Information
Product Announcement.
Click for Full Prescribing Information, including Indication, BOXED WARNING, and Important Safety Information
Indication
Multiple Sclerosis
Status
- US Launched on February 13, 2023 by Cycle Pharma.
- Exclusive License Agreement with Cycle Pharmaceuticals Ltd. for Commercialization of Tascenso ODT in the USA on March 4th, 2022.
- Final approval for 0.25mg & 0.5mg.
Product Advantages
Orally disintegrating tablet format is generally known to be of particular relevance to patients with swallowing difficulties. Handa ODT product is relevant to patients who have some level of dysphagia, patients who need to switch therapies due to efficacy or tolerability issues with current therapy, and patients who prefer ODT administration.
Market Size
According to the data in 2024 annual report of the brand company, the total sales of the brand drug were 552 million.
Our Products.
Handa offers an ever expanding portfolio of products targeting key therapeutic areas.
PHYRAGO™ is Efficacious with Concomitant PPI/H2s.
PHYRAGO™ Solves Known Problems in Patients with Elevated Gastric Ph(1)
oncore™ PLatform
Research & Development.
Complimentary Focus
Handa is focused on developing high-quality prescription medications in two complementary areas: proprietary therapeutics that address significant unmet patient needs, and high-barrier-to-entry generic drugs.
Development Process
Optimizing Therapies for Underserved Oncology and Neurology Patients.
Reduced Pharmacokinetic Variability: Minimizes adverse events resulting from drug overexposure and avoids the loss of efficacy caused by underexposure.
Overcoming GI and pH Barriers: ONCORE™ Platform effectively neutralizes the GI pH effect that limits many targeted therapies. This eliminates food-effect variables and removes the strict, burdensome restrictions associated with Proton Pump Inhibitors (PPIs) and acid-reducing agents.
Advanced ODT Applications: Beyond traditional pills, the ONCORE™ platform is highly adaptable to Orally Disintegrating Tablet (ODT) formats. It offers superior taste-masking and significantly reduced mucosal irritation, which is a critical advantage for neurology and oncology patients who suffer from swallowing difficulties.
Advancing Oncology Therapeutics Through Innovative Formulation.
To explore partnership opportunities or learn more about our innovative pipeline, please get in touch.
Milestone Achievement
Handa Pharma is a clinical-stage pharmaceutical company at the forefront of oncology and neurology therapeutics, pioneering advancements through our proprietary ONCORE™ platform.
Game-Changing Update
ONCORE™ technology enables the precise formulation and delivery of critical treatments, ensuring therapeutic efficacy, reducing safety risks, and improving patient tolerability and compliance.
Global Expansion
Our focus lies in overcoming longstanding challenges such as poor solubility, food effects, and pH sensitivity - particularly for tyrosine kinase inhibitors (TKI’s) - by transforming how these drugs are formulated and delivered.
Innovation
Our commitment to innovation is validated by the FDA approval of Phyrago™, a next-generation dasatinib formulation engineered using ONCORE™to have enhanced pharmacokinetic performance compared to Sprycel®.
Clinical Progress
We are further driving clinical progress with a robust pipeline of novel oncology and neurology assets, strategically designed to address significant unmet medical needs within the landscape.
New Chemical Entities.
- Handa Pharma is interested in partnering to apply its ONCORE™ technology to New Chemical Entities (NCEs).
- This focuses on working with partners who have novel drug candidates but face challenges with formulation, delivery, or bioavailability.